Serplulimab (Hansizhuang)

General information

Class/mechanism: PD-1 receptor antibody.
Route: IV
Extravasation: no information

For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.

Toxicity management

• Immunotherapy toxicity management

Diseases for which it is used

• MSI-H or dMMR solid tumors (tissue-agnostic)
• Small cell lung cancer

History of changes in NMPA indication

• 2022-03-25: Approved for the treatment of adult patients with advanced unresectable or metastatic MSI-H (Microsatellite Instability-High) solid tumors that have failed to respond to previous standard treatments.

Also known as

• Code name: HLX10
• Brand name: Hansizhuang